The Form 4 filing, a report of an insider's stock trades, was filed on Oct. 29, 2026. The trades took place one day earlier. It lists Martine A. Rothblatt as United Therapeutics' chairperson and CEO.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-28 |
| Date of Latest Transaction | 2026-10-28 |
| Buy/Sell | sell |
| Transaction Count | 6 |
| Shares Transacted | 9,500 |
| Price | $585.49 |
| Total Transaction Value | $5,562,190.05 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-10-29 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of United Therapeutics (UTHR) shares, reported with transaction code S. The record covers six transactions by one insider in one filing.
What was the average price of the transaction?
The average sale price was $585.49 per share, rounded to the nearest cent. The available details do not give a separate price for each of the six transactions.
How did this transaction affect the insider's holdings?
The sale reduced her reported holdings by 9,500 shares, leaving 324,443 shares. She sold 2.84% of the shares she held before the sale.
What's the total transaction value?
The six sale transactions had a total value of $5,562,190.05, rounded to the nearest cent. This total covers all 9,500 shares sold.
Are there any special circumstances around this transaction?
The transaction details include a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The available information does not show which sales the reference covers.
Footnote text is unavailable, so the plan's scope and terms cannot be confirmed. Its start date and trade schedule are unknown. The reference alone does not show whether the trades met the rule's requirements.
For research purposes only; not investment advice.